摘要
目的观察xTAG液相芯片技术检测经支气管针吸活检术(TBNA)细胞学标本及配对组织学标本中表皮生长因子受体(EGFR)基因突变情况,比较两者有无差别。方法收集非小细胞肺癌组织标本及配对TBNA细胞学标本,两组样本分别用xTAG液相芯片技术进行EGFR基因(19和21)突变分析。结果EGFR外显子19在非小细胞肺癌组织学标本中的突变率为30.0%(9/30),在TBNA细胞学标本的突变率为26.7%(8/30);EGFR外显子21在非小细胞肺癌组织标本中的突变率为13.3%(4/30),在TBNA细胞学标本的突变率为13.3%(4/30)。在13例患者肿瘤组织中检测出外显子19或21突变,其中12例TBNA细胞学标本中也检测出外显子19或21突变。组织学标本为EGFR野生型,其配对的TBNA细胞学标本也均为野生型,肿瘤组织学标本和配对TBNA细胞学标本的EGFR突变检测结果总符合率为79%。结论TBNA细胞学是一种诊断肺癌及其纵隔淋巴结转移的准确、敏感和特异的方法。用xTAG液相芯片技术可以有效地检测TBNA细胞学标本中EGFR基因突变状态。
Objective To observe epidermal growth factor receptor (EGFR) gene mutation in transbronchial needle aspiration (TBNA) cytology specimens and tissue specimens using SurPlex- xTAG70plex liquidchip. Methods DNA was extracted from the TBNA samples,and EGFR gene (exon 19 and 21) mutation was analyzed using SurPlex-xTAG70plex liquidchip. Results The mutation rates of EGFR exon 19 and 21 were 30.0%(9/30) and 13.3%(4/30) respectively in tumor tissues,while 26.7% (8/30) and 13.3 % (4/30) in TBNA samples. Thirteen patients had either EGFR exon 19 or 21 mutation in tumor tissues,12 of them were detected to have the same mutation in TBNA samples. All the patients who had wild-type EGFR in tumor tissues were detected to have wild-type in TBNA samples as well. 79% of EGFR mutation status in tumor tissues was consistent with that in the TBNA samples. Conclusions The detection of exon 19 and 21 of EGFR gene using SurPlex-xTAGT0plex liquidchip is feasible on fihro- hronehoscopy cytological samples with the same reliability offered by the histological samples obtained from the same patient.
出处
《国际呼吸杂志》
2015年第22期1681-1685,共5页
International Journal of Respiration
基金
佛山市医学类科技攻关项目(201208221)